A roadmap for the early detection and diagnosis of cancer

Abstract

than likely, the success of surufatinib is attributable to both its novel mechanism of action and favourable business decisions around its development. In addition, we do not yet know how surufatinib will fit into the complex treatment algorithm for NETs. Evidence regarding sequence of therapies is a crucial need in the field, although might be impractical to study in prospective clinical trials. We also need to study mechanisms of resistance to tyrosine kinase inhibitors, develop and validate predictive biomarkers, understand reasons for heterogeneity in objective response, and identify better quantitative radiological response criteria in the setting of angiogenesis inhibition. Last, but not least, we must also keep patients with NETs at the core of how we think about optimal treatment strategies. Given the chronicity of well differentiated NETs, these patients will experience an accumulation of toxicities over years that include non-trivial drug side-effects, particularly with tyrosine kinase inhibitors.PLK reports receiving research funding to her institution from Advanced Accelerator Applications, Brahms (Thermo-Fisher Scientific), Ipsen, Lexicon Pharmaceuticals, and Xencor; and reports serving on scientific advisory board meetings for and receiving honorarium from Advance Accelerator Applications and Ipsen.

Early cancer diagnosis: reaching targets across whole populations amidst setbacks

“…To this end, the Cancer Research UK Early Detection and Diagnosis Roadmap Steering Group have highlighted the need for a paradigm shift in cancer early diagnosis. 12,13 The detailed roadmap calls for a more unified multi-disciplinary and multi-sector effort to advance cancer early detection and diagnosis. It outlines a range of avenues for investigation to aid early diagnosis-from cancer biology, including precancer evolution and circulating tumour DNA, to risk prediction models, artificial intelligence, modern technological advances and finally commercialisation of products for scale-up and community reach.…”

Early detection of prostate gland and breast cancer risk based on routine check-up data using survival analysis trees for left-truncated and right-censored data

“…Early detection of cancer is crucial for providing appropriate care to the patient and can improve both prognosis and survival [1–5]. The current detection strategies use specific screening tests that require substantial resources, e.g., serum Prostate-Specific Antigen (PSA) level for Prostate Gland Cancer (PGC), mammography, an X-ray modality, for detecting early signs of Breast Cancer (BC), and clinical breast examination (CBE), a physical examination to recognize abnormalities in the breast [6].…”

Erratum for the Report “PML Regulates Apoptosis at Endoplasmic Reticulum by Modulating Calcium Release” by C. Giorgi, K. Ito, H.-K. Lin, C. Santangelo, M. R. Wieckowski, M. Lebiedzinska, A. Bononi, M. Bonora, J. Duszynski, R. Bernardi, R. Rizzuto, C. Tacchetti, P. Pinton, P. P. Pandolfi

“…Sometimes, though, the magnitude of the impact is underappreciated. Pharmacologist David Crosby, head of prevention and early detection research at Cancer Research UK, and his colleagues emphasized the earlydetection effect on treatment results: ì57% of people with lung cancer survive their disease for 5 years or more when diagnosed at stage I compared with only 3% of those diagnosed at stage IVî (1).…”